ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 385

Systemic Inflammation In Patients With Inflammatory Joint Disease Does Not Influence Statin Dose Needed To Obtain Low Density Lipoprotein Cholesterol Goal In Cardiovascular Prevention

Silvia Rollefstad1, Eirik Ikdahl2, Tore K. Kvien3,4, Terje R. Pedersen4,5, Ingar Holme6 and Anne G. Semb2, 1Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Faculty of Medicine, University of Oslo, Oslo, Norway, 5Centre of Preventive Medicine, Oslo University Hospital-Ullevaal, Oslo, Norway, 6Department of biostatistics, epidemiology and health economics, Oslo University Hospital-Ullevaal, Oslo, Norway

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Inflammation, Lipids, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects I: Comorbidities in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: There is a lipid paradox in rheumatoid arthritis (RA): despite low lipids influenced by systemic inflammation, there is an increased risk of cardiovascular (CV) disease. Our aim was to describe doses of statins needed to obtain recommended lipid goals in patients with inflammatory joint disease (IJD), including RA, ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Further, to evaluate if baseline systemic inflammation and lipid levels were associated with statin dose (conventional vs. intensive) needed to obtain guideline recommended low density lipoprotein cholesterol (LDL-c) goal in patients with IJD.

Methods : CV risk stratification was performed at the first consultation in a preventive cardio-rheuma clinic in 202 patients (RA: n=124, AS: n=52, PsA: n=26). The patients were classified to either primary or secondary CV prevention with lipid lowering (LL) treatment, or to have low risk with no indication for medical intervention. LL treatment was initiated with statins and adjusted until at least two lipid targets were achieved. Any side effects/intolerance was recorded. Intensive LL treatment was defined as rosuvastatin ≥ 20 mg, atorvastatin and simvastatin ≥ 80 mg, and conventional LL treatment was defined as all lower doses.

Results: Type or dosage of statins and number of dose adjustments to obtain lipid goals were similar in patients with RA, AS and PsA. There was equal need for change of statin medication across the 3 IJD’s due to intolerance/adverse event(s). In a univariate analysis neither systemic inflammation (CRP/ESR: p-value 0.10 and 0.11, respectively) nor lipid levels (LDL-c/total cholesterol (TC): p-value 0.17 and 0.34, respectively) at baseline were associated with the dose of statin needed to achieve LDL-c targets (Figure).

Conclusion: Systemic inflammation or lipid levels did not influence statin dose (conventional or intensive) needed to obtain guideline recommended lipid targets in CV prevention. Whether the background inflammation in IJD patients over time influences the CV risk reduction related to statins is yet unknown.

 SHAPE  * MERGEFORMAT

Figure: Doses of lipid lowering treatment (LLT) needed to achieve LDL-c goals

Baseline:

s


Disclosure:

S. Rollefstad,
None;

E. Ikdahl,
None;

T. K. Kvien,
None;

T. R. Pedersen,

Pfizer, Merck-Schering Plough, AstraZeneca,

5;

I. Holme,

Pfizer, Merck/Schering Plough, AstraZeneca, Roche,

5;

A. G. Semb,

Merck/Schering-Plough, Abbott, BMS, Pfizer/Wyeth, Genentech and Roche,

5.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-inflammation-in-patients-with-inflammatory-joint-disease-does-not-influence-statin-dose-needed-to-obtain-low-density-lipoprotein-cholesterol-goal-in-cardiovascular-prevention/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.